Format
Sort by

Send to

Choose Destination

Links from

Items: 1 to 20 of 193

1.

Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.

Canonici A, Gijsen M, Mullooly M, Bennett R, Bouguern N, Pedersen K, O'Brien NA, Roxanis I, Li JL, Bridge E, Finn R, Siamon D, McGowan P, Duffy MJ, O'Donovan N, Crown J, Kong A.

Oncotarget. 2013 Oct;4(10):1592-605.

2.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067. Epub 2011 Nov 28.

3.

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.

Oncogene. 2014 Jun 26;33(26):3422-31. doi: 10.1038/onc.2013.308. Epub 2013 Aug 5.

4.

ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer.

Feldinger K, Generali D, Kramer-Marek G, Gijsen M, Ng TB, Wong JH, Strina C, Cappelletti M, Andreis D, Li JL, Bridges E, Turley H, Leek R, Roxanis I, Capala J, Murphy G, Harris AL, Kong A.

Oncotarget. 2014 Aug 30;5(16):6633-46.

5.

Dacomitinib (PF-00299804), an irreversible Pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to trastuzumab and lapatinib.

Kalous O, Conklin D, Desai AJ, O'Brien NA, Ginther C, Anderson L, Cohen DJ, Britten CD, Taylor I, Christensen JG, Slamon DJ, Finn RS.

Mol Cancer Ther. 2012 Sep;11(9):1978-87. doi: 10.1158/1535-7163.MCT-11-0730. Epub 2012 Jul 3.

6.

Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.

Tseng PH, Wang YC, Weng SC, Weng JR, Chen CS, Brueggemeier RW, Shapiro CL, Chen CY, Dunn SE, Pollak M, Chen CS.

Mol Pharmacol. 2006 Nov;70(5):1534-41. Epub 2006 Aug 3.

7.

Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers.

Garrett JT, Sutton CR, Kurupi R, Bialucha CU, Ettenberg SA, Collins SD, Sheng Q, Wallweber J, Defazio-Eli L, Arteaga CL.

Cancer Res. 2013 Oct 1;73(19):6013-23. doi: 10.1158/0008-5472.CAN-13-1191. Epub 2013 Aug 5.

8.

Dual mTORC1/2 and HER2 blockade results in antitumor activity in preclinical models of breast cancer resistant to anti-HER2 therapy.

García-García C, Ibrahim YH, Serra V, Calvo MT, Guzmán M, Grueso J, Aura C, Pérez J, Jessen K, Liu Y, Rommel C, Tabernero J, Baselga J, Scaltriti M.

Clin Cancer Res. 2012 May 1;18(9):2603-12. doi: 10.1158/1078-0432.CCR-11-2750. Epub 2012 Mar 8.

9.

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.

Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.

Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x. Epub 2012 Nov 2.

PMID:
23117856
10.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004. Epub 2014 Aug 12.

PMID:
25128455
11.

HER2 phosphorylation is maintained by a PKB negative feedback loop in response to anti-HER2 herceptin in breast cancer.

Gijsen M, King P, Perera T, Parker PJ, Harris AL, Larijani B, Kong A.

PLoS Biol. 2010 Dec 21;8(12):e1000563. doi: 10.1371/journal.pbio.1000563. Erratum in: PLoS Biol. 2016 Mar;14(3):e1002414.

12.

Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.

Wainberg ZA, Anghel A, Rogers AM, Desai AJ, Kalous O, Conklin D, Ayala R, O'Brien NA, Quadt C, Akimov M, Slamon DJ, Finn RS.

Mol Cancer Ther. 2013 Apr;12(4):509-19. doi: 10.1158/1535-7163.MCT-12-0507. Epub 2013 Feb 8.

13.

ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor.

Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L.

Oncogene. 2008 Aug 28;27(37):5019-32. doi: 10.1038/onc.2008.149. Epub 2008 May 12.

PMID:
18469855
14.

EGFR over-expression and activation in high HER2, ER negative breast cancer cell line induces trastuzumab resistance.

Dua R, Zhang J, Nhonthachit P, Penuel E, Petropoulos C, Parry G.

Breast Cancer Res Treat. 2010 Aug;122(3):685-97. doi: 10.1007/s10549-009-0592-x. Epub 2009 Oct 27.

PMID:
19859802
15.

The combination of gefitinib and RAD001 inhibits growth of HER2 overexpressing breast cancer cells and tumors irrespective of trastuzumab sensitivity.

Dragowska WH, Weppler SA, Qadir MA, Wong LY, Franssen Y, Baker JH, Kapanen AI, Kierkels GJ, Masin D, Minchinton AI, Gelmon KA, Bally MB.

BMC Cancer. 2011 Oct 1;11:420. doi: 10.1186/1471-2407-11-420.

16.

Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer.

Mohd Nafi SN, Generali D, Kramer-Marek G, Gijsen M, Strina C, Cappelletti M, Andreis D, Haider S, Li JL, Bridges E, Capala J, Ioannis R, Harris AL, Kong A.

Oncotarget. 2014 Aug 15;5(15):5934-49.

17.

The anti-erbB3 antibody MM-121/SAR256212 in combination with trastuzumab exerts potent antitumor activity against trastuzumab-resistant breast cancer cells.

Huang J, Wang S, Lyu H, Cai B, Yang X, Wang J, Liu B.

Mol Cancer. 2013 Nov 11;12(1):134. doi: 10.1186/1476-4598-12-134.

18.

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.

Valabrega G, Capellero S, Cavalloni G, Zaccarello G, Petrelli A, Migliardi G, Milani A, Peraldo-Neia C, Gammaitoni L, Sapino A, Pecchioni C, Moggio A, Giordano S, Aglietta M, Montemurro F.

Breast Cancer Res Treat. 2011 Nov;130(1):29-40. doi: 10.1007/s10549-010-1281-5. Epub 2010 Dec 9.

PMID:
21153051
19.

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.

Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y, Zhang J.

Tumour Biol. 2012 Oct;33(5):1349-62. doi: 10.1007/s13277-012-0383-6. Epub 2012 Apr 11.

PMID:
22492237
20.

Autophagy-related gene 12 (ATG12) is a novel determinant of primary resistance to HER2-targeted therapies: utility of transcriptome analysis of the autophagy interactome to guide breast cancer treatment.

Cufí S, Vazquez-Martin A, Oliveras-Ferraros C, Corominas-Faja B, Urruticoechea A, Martin-Castillo B, Menendez JA.

Oncotarget. 2012 Dec;3(12):1600-14.

Items per page

Supplemental Content

Write to the Help Desk